CAR T-cell therapy (Outpace Bio)

N/A

Report date: 2025/01/26 19:05:33

Base Information

Drug NameCAR T-cell therapy (Outpace Bio)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionInterleukin-2 receptor modulatorsInterleukin-15 receptors modulators

TargetsInterleukin-2 receptorInterleukin-15 receptors

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOutpace Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesOutpace Bio Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A